RxDoctor Payments Data

Erin Radominski

Acute Care · Dayton, OHNPI 1659865103

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,199in general payments, 2019–2025

Across 242 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$856
  • Sanofi$604
  • Regeneron Healthcare Solutions, Inc.$529
  • Boehringer Ingelheim$322
  • Amgen$213
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,96395%
  • Education$2365%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,199 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter341$354,193
OfevNintedanib Esylate19$250,636
Breztri AerosphereBudesonide/Glycopyr/Formoterol74$67,248
Breo ElliptaFluticasone/Vilanterol46$24,001
Spiriva RespimatTiotropium Bromide26$16,938
SymbicortBudesonide/Formoterol Fumarate39$15,143
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$13,414
Albuterol Sulfate HfaAlbuterol Sulfate220$7,204
Azithromycin284$3,836
Pirfenidone11$3,437
Roflumilast27$2,365
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$2,222
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$1,363
Varenicline Tartrate13$1,355
Montelukast Sodium131$792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$856$378,194387 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$322$280,98868 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,105$82,390113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.

Other acute care in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →